Business model

Helsinn out-licenses its products to commercial partners in its global distribution network while promoting and distributing to the cancer-care community in the US through our subsidiary Helsinn Therapeutics.

Process

Process

We start the process with the identification of innovative NCEs in the development phase, which are then in-licensed by acquiring the worldwide rights.

Once we have a product aligned with our mission and portfolio, we utilise our integrated capabilities and our in-house knowledge to complete development, and secure marketing approvals and commercialization worldwide either directly or through our partners.